A Phase 1 interventional study of PCI-32765 in B-cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-24.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 49th largest by enrollment, is the only one that started in 2011, is one of 17 in phase 1, and was the 4th registered.
2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 39 across 1,605 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 31st largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2011, is one of 13 in phase 1, and was the 12th registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL).
This is a Phase 1b, open-label, parallel-group, nonrandomized, multicenter study of PCI 32765 420 mg once daily oral (PO) administration in combination with 2 different chemotherapy regimens in subjects with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed CLL or SLL and satisfying at least 1 of the following criteria for requiring treatment:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PCI-32765
Drug: PCI-32765
420 mg daily
Incidence of Prolonged Hematologic Toxicity Started in Cycle 1
Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib
Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0
Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Overall Incidence of Serious Adverse Events (SAEs)
Time frame: From First day of dose to 30 days after last dose of any study medication. Participants were followed with a median follow-up time of 15.8 months.
Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits.
Time frame: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline
Time frame: From first response assessment to last response assessment. Participants were followed with a median follow-up time of 15.8 months.
Progression Free Survival Rate at 12 Months
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size.
Time frame: From first dose of any study medication to 12 months after first dose to progressive disease or death or the last clinical assessment before receiving new anticancer therapy or loss to follow-up, whichever occured the earliest.
| Milestone | PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) | PCI-32765 Plus Bendamustine/Rituximab (BR) |
|---|---|---|
| Started | 3 | 30 |
| Completed | 3 | 21 |
| Not completed | 0 | 9 |
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Incidence of Prolonged Hematologic Toxicity Started in Cycle 1 | 0 (0 to 11.6) | 0 (NA to NA) |
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib | 53.3 | 33.3 |
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0 | 66.7 | 0 |
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Overall Incidence of Serious Adverse Events (SAEs) | 20 | 33.3 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. Assessment of response to treatment will be done every 2 cycles for the first 6 months and then every 3 months thereafter until disease progression or prior to the administration of a new anticancer therapy and at follow-up visits.
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR]) | 93.3 (77.9 to 99.2) | 100 (NA to NA) |
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline | 76.2 (52.8 to 91.8) | — |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size.
| Percentage of Participants | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI- 32765 Plus Fludarabine/ Cyclophosphamide/ Rituximab (FCR) |
|---|---|---|
| Progression Free Survival Rate at 12 Months | 85.9 (66.7 to 94.5) | 100 (100 to 100) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PCI-32765 Plus Bendamustine/Rituximab (BR) | — | 6/30 (20%) | 30/30 (100%) |
| PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR) | — | 1/3 (33.3%) | 3/3 (100%) |
| Event | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR) |
|---|---|---|
| GastritisGastrointestinal disorders | 0/30 | 1/3 |
| Viral InfectionInfections and infestations | 0/30 | 1/3 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/30 | 0/3 |
| CellulitisInfections and infestations | 2/30 | 0/3 |
| DehydrationMetabolism and nutrition disorders | 1/30 | 0/3 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 1/30 | 0/3 |
| Event | PCI-32765 Plus Bendamustine/Rituximab (BR) | PCI-32765 Plus Fludarabine/ Cyclophosphamide/Rituximab (FCR) |
|---|---|---|
| HypocalcaemiaMetabolism and nutrition disorders | 3/30 | 3/3 |
| DiarrhoeaGastrointestinal disorders | 21/30 | 1/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/30 | 2/3 |
| AnaemiaBlood and lymphatic system disorders | 2/30 | 2/3 |
| NauseaGastrointestinal disorders | 20/30 | 2/3 |
| HypomagnesaemiaMetabolism and nutrition disorders | 4/30 | 2/3 |
| FatigueGeneral disorders | 14/30 | 0/3 |
| NeutropeniaBlood and lymphatic system disorders | 12/30 | 1/3 |
| Upper respiratory tract infectionInfections and infestations | 11/30 | 1/3 |
| Dry mouthGastrointestinal disorders | 4/30 | 1/3 |
| Age, Continuous(Years) | PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) | PCI-32765 Plus Bendamustine/Rituximab (BR) | Total |
|---|---|---|---|
| Mean | 56.3 ± 1.53 | 61.3 ± 9.58 | 60.8 ± 9.24 |
| Age, Categorical(Participants) | PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) | PCI-32765 Plus Bendamustine/Rituximab (BR) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 19 | 22 |
| >=65 years | 0 | 11 | 11 |
| Sex: Female, Male(Participants) | PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) | PCI-32765 Plus Bendamustine/Rituximab (BR) | Total |
|---|---|---|---|
| Female | 0 | 5 | 5 |
| Male | 3 | 25 | 28 |
| Region of Enrollment(participants) | PCI-32765 Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) | PCI-32765 Plus Bendamustine/Rituximab (BR) | Total |
|---|---|---|---|
| United States | 3 | 30 | 33 |
The record gives a start of Feb 2011, a primary completion of Nov 2012 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →